Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

New Test Developed for Early Lyme Disease Detection

By Drug Discovery Trends Editor | April 25, 2016

As part of the EU “ID Lyme” project, the infection immunology working group at the Institute for Hygiene and Applied Immunology at the Center for Pathophysiology, Infectiology and Immunology at the Medical University of Vienna is working on developing of a new test for early detection of Lyme disease (borreliosis). This will  improve the ability to detect an active infection more easily than before so that healthy people with Lyme disease antibodies in their blood do not receive unnecessary antibiotic treatment and so that appropriate treatments can be initiated at an early stage. The antibody tests that are currently available only provide a reliable result 3 – 4 weeks after infection has occurred. 

“Unfortunately, the current standard laboratory test is often unable to detect Lyme disease at an early stage of the infection,” explains Hannes Stockinger, Head of the Institute for Hygiene and Applied Immunology of the Center for Pathophysiology, Infectionology and Immunology of MedUni Vienna. “On top of that, the current test often interprets a mere antibody reaction as an infection and people are treated with antibiotics unnecessarily, because the infection is way in the past or is already completely resolved.” 

“Not every tick bite necessarily results in an infection and not every positive Lyme disease test means that infection is present. That’s the tricky bit,” adds Gerold Stanek from the similarly named Institute and Center at MedUni Vienna and one of the pioneers of research into Lyme disease in Austria. For example, a lot of hunters, who obviously spend a lot of time in woods and meadows, are really healthy, even though they display antibodies to Lyme disease, i.e. they have previously and repeatedly come into contact with it. 

New test allows more accurate and earlier diagnosis

The current test is only able to analyze part of the human immune system, namely the B-cells but not the T-cells, which are needed as helper cells to fight the infection and whose activity indicates the presence of an infection. The MedUni Vienna immunology experts are therefore helping to develop the world’s first point-of-care test, which could be used to detect an active infection so that patients could start the appropriate treatment. The test, which is known as the “Ixodes Kit” should be in clinical use in the autumn of 2016, said the scientists, speaking on the occasion of World Immunology Day 2016. Ixodes is the scientific name for hard-bodied ticks. 

Best (April) climate for ticks 

Lyme disease is particularly common in Central Europe and in the Scandinavian countries. As a result of global warming, its area of spread is continuously moving northwards. Tick activity is starting earlier and earlier. In Austria itself, we currently have the best climate for ticks, as Stanek emphasizes: “Ticks become active when the ground temperature rises above 7°C, as is now the case in Spring.”  

So far there is no vaccination available against Lyme disease, such as there is for Tick-Borne Encephalitis (TBE) that is also spread via tick bites. Every year around 70,000 people in Austria develop Lyme disease after being bitten by a deer tick. Approximately one in every four ticks carries Lyme disease. So-called erythema migrans is a sure sign of infection with tick-borne Lyme disease. However, this only occurs in around one third of patients. If the bacterial infection is not detected in good time it can lead to serious problems such as joint inflammation and even very painful infections of the nerve roots resulting in paralysis or memory loss. 

Source: Medical University of Vienna


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50